Satellos Bioscience Inc. Common Stock (NASDAQ:MSLE) — Market Cap & Net Worth
Market Cap & Net Worth: Satellos Bioscience Inc. Common Stock (MSLE)
Satellos Bioscience Inc. Common Stock (NASDAQ:MSLE) has a market capitalization of $160.19 Million ($160.19 Million) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17327 globally and #4053 in its home market, demonstrating a 3.85% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Satellos Bioscience Inc. Common Stock's stock price $9.99 by its total outstanding shares 20831190 (20.83 Million). Review Satellos Bioscience Inc. Common Stock total liabilities to assess the company's total debt and financial obligations.
Satellos Bioscience Inc. Common Stock Market Cap History: 2026 to 2026
Satellos Bioscience Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $208.10 Million to $208.10 Million (0.00% CAGR).
Satellos Bioscience Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Satellos Bioscience Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MSLE by Market Capitalization
Companies near Satellos Bioscience Inc. Common Stock in the global market cap rankings as of August 1, 2026.
Key companies related to Satellos Bioscience Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Satellos Bioscience Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Satellos Bioscience Inc. Common Stock's market cap moved from $208.10 Million to $ 208.10 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $208.10 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Satellos Bioscience Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $160.19 Million USD |
| MoneyControl | $160.19 Million USD |
| MarketWatch | $160.19 Million USD |
| marketcap.company | $160.19 Million USD |
| Reuters | $160.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small m… Read more